AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
The ASX/S&P 200 is rallying from the positive news on the trade front and with a rising oil price environment. Two stocks that are riding on the back of the markets are from health care and consumer discretionary sectors. The two stocks are as follows:
RESONANCE HEALTH LIMITED (ASX:RHT) â The companyâs ground-breaking machine learning solution for the quantification of liver iron concentration FerriSmart has received 510 (K) clearance from the US FDA. FerriSmart returns a liver iron quantification result within seconds and is efficient in analyzing MRI images from most scanner makes and models. The company had a 17% increase in revenue from FY16/17. The financial results for the year are underlined by a net profit of $224,619, compared to a net loss of $304,217 in the previous financial year which was driven by increase in total revenue for the year of $2,896,395, up from the previous financial yearâs total of $2,485,332, posting an increase of 17%. The companyâs receipts from customers increased to $2,652,132 which is a 16% increase from the previous year. The stock price surged up by an attractive 130.769% as at December 3, 2018 to $0.060 which is near its 52-week high and has witnessed an 8.33% change over the past six months.
AQUIS ENTERTAINMENT LIMITED (ASX:AQS) â The cash and cash equivalents at the end of September 30, 2018 was of $5.643 million. However, revenue from operations is down by 3.6% to $12,317,421 and hence the total loss for the year to shareholders Aquis entertainment has increased by 53.3% to $2,156,212. With the expectation of cash flows and positive EBITDA for the full financial year and the half year results achieved, have been in line with those targets and a strong budget which is set for the year. Also, net cash outflows from operations for the period were $235,705 which is lower compared to 30 June 2017 outflow of $2,288,562. Total operating expenses were of $14,473,633 which were lower than the prior year $17,983,724 by 19.5% which shows that the current cost reduction program is reaping real, ongoing savings benefits. The stock price surged up by as much as 45% as at December 3, 2018 to $0.029 and has witnessed an -60.00% change over the past six months.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
